Abstract
FTY720 (Fingolimod) reduces multiple sclerosis disease activity by inducing lymphopenia and inhibiting lymphocyte re-entry from lymph nodes.
Peripheral lymphocyte reconstitution following drug discontinuation has been considered relatively rapid (2-4weeks), based on short-term studies.
We investigated the kinetics of lymphocyte reconstitution in MS patients in open label extension phases of FTY720 clinical trials who discontinued therapy after prolonged use (>1-5years), and examined histological features of a mediastinal lymph node obtained from a lymphopenic FTY720 patient.......Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309